{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:29Z","timestamp":1792787909002,"version":"4.5.0"},"reference-count":238,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212BAB216051"],"award-info":[{"award-number":["20212BAB216051"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212BAB216047"],"award-info":[{"award-number":["20212BAB216047"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160371"],"award-info":[{"award-number":["82160371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100869"],"award-info":[{"award-number":["82100869"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangxi Province Thousands of Plans","award":["jxsq2023201105"],"award-info":[{"award-number":["jxsq2023201105"]}]},{"name":"Hengrui Diabetes Metabolism Research Fund","award":["Z-2017-26-2202-4"],"award-info":[{"award-number":["Z-2017-26-2202-4"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03173-5","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T05:44:25Z","timestamp":1775367865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sweet relief: exploring mechanisms and therapeutic approaches of sodium-glucose cotransporter-2 inhibitors in cardiovascular-kidney metabolic syndrome"],"prefix":"10.1186","volume":"25","author":[{"given":"Jiaxin","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"issue":"2","key":"3173_CR1","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/j.cpcardiol.2023.102344","volume":"49","author":"SA Sebastian","year":"2024","unstructured":"Sebastian SA, Padda I, Johal G. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. Curr Probl Cardiol. 2024;49(2):102344.","journal-title":"Curr Probl Cardiol"},{"key":"3173_CR2","doi-asserted-by":"crossref","unstructured":"Longo M et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci, 2019;20(9).","DOI":"10.3390\/ijms20092358"},{"issue":"9","key":"3173_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.tem.2011.04.007","volume":"22","author":"SH Choi","year":"2011","unstructured":"Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab. 2011;22(9):353\u201363.","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"3173_CR4","doi-asserted-by":"publisher","first-page":"e00129","DOI":"10.1002\/edm2.129","volume":"3","author":"O Schnell","year":"2020","unstructured":"Schnell O, et al. Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes. Endocrinol Diabetes Metab. 2020;3(3):e00129.","journal-title":"Endocrinol Diabetes Metab"},{"key":"3173_CR5","doi-asserted-by":"publisher","first-page":"101549","DOI":"10.1016\/j.molmet.2022.101549","volume":"64","author":"A Elrakaybi","year":"2022","unstructured":"Elrakaybi A, et al. Cardiovascular protection by SGLT2 inhibitors - Do anti-inflammatory mechanisms play a role? Mol Metab. 2022;64:101549.","journal-title":"Mol Metab"},{"issue":"6","key":"3173_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00467-018-4005-4","volume":"34","author":"K Daenen","year":"2019","unstructured":"Daenen K, et al. Oxidative stress in chronic kidney disease. Pediatr Nephrol. 2019;34(6):975\u201391.","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"3173_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41574-019-0219-1","volume":"15","author":"E Larqu\u00e9","year":"2019","unstructured":"Larqu\u00e9 E, et al. From conception to infancy - early risk factors for childhood obesity. Nat Rev Endocrinol. 2019;15(8):456\u201378.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"3173_CR8","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.pcl.2015.05.013","volume":"62","author":"CL Brown","year":"2015","unstructured":"Brown CL, et al. Addressing Childhood Obesity: Opportunities for Prevention. Pediatr Clin North Am. 2015;62(5):1241\u201361.","journal-title":"Pediatr Clin North Am"},{"issue":"20","key":"3173_CR9","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606\u201335.","journal-title":"Circulation"},{"issue":"20","key":"3173_CR10","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation. 2023;148(20):1636\u201364.","journal-title":"Circulation"},{"issue":"18","key":"3173_CR11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling\/Autophagy Hypothesis. Circulation. 2022;146(18):1383\u2013405.","journal-title":"Circulation"},{"issue":"1","key":"3173_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","volume":"21","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022;21(1):232.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"3173_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"3173_CR14","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"3173_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"3173_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"key":"3173_CR17","doi-asserted-by":"crossref","unstructured":"Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care, 2020;43(Suppl 1):S98\u2013110.","DOI":"10.2337\/dc20-S009"},{"issue":"2","key":"3173_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","volume":"25","author":"DN Koye","year":"2018","unstructured":"Koye DN, et al. The Global Epidemiology of Diabetes and Kidney Disease. Adv Chronic Kidney Dis. 2018;25(2):121\u201332.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"3173_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.CIR.0000028099.24188.C4","volume":"106","author":"LH Opie","year":"2002","unstructured":"Opie LH, Parving HH. Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection? Circulation. 2002;106(6):643\u20135.","journal-title":"Circulation"},{"issue":"1","key":"3173_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","volume":"22","author":"M Marassi","year":"2023","unstructured":"Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;22(1):195.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"3173_CR21","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1007\/s11695-019-03952-y","volume":"29","author":"S Pouwels","year":"2019","unstructured":"Pouwels S, et al. Obesity Surgery and Anesthesiology Risks: a Review of Key Concepts and Related Physiology. Obes Surg. 2019;29(8):2670\u20137.","journal-title":"Obes Surg"},{"key":"3173_CR22","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.molmet.2022.101515","volume":"62","author":"X Chen","year":"2022","unstructured":"Chen X, et al. Advances in the study of RNA-binding proteins in diabetic complications. Mol Metab. 2022;62:101515.","journal-title":"Mol Metab"},{"key":"3173_CR23","doi-asserted-by":"publisher","first-page":"1114424","DOI":"10.3389\/fendo.2023.1114424","volume":"14","author":"J Wu","year":"2023","unstructured":"Wu J, et al. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023;14:1114424.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3173_CR24","doi-asserted-by":"crossref","unstructured":"Artasensi A et al. Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options. Molecules, 2023;28(7).","DOI":"10.3390\/molecules28073094"},{"issue":"7","key":"3173_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/CIRCRESAHA.121.318093","volume":"128","author":"M Koenen","year":"2021","unstructured":"Koenen M, et al. Obesity, Adipose Tissue and Vascular Dysfunction. Circ Res. 2021;128(7):951\u201368.","journal-title":"Circ Res"},{"issue":"6865","key":"3173_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/414813a","volume":"414","author":"M Brownlee","year":"2001","unstructured":"Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813\u201320.","journal-title":"Nature"},{"issue":"9","key":"3173_CR27","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","volume":"107","author":"F Giacco","year":"2010","unstructured":"Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058\u201370.","journal-title":"Circ Res"},{"issue":"1","key":"3173_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","volume":"18","author":"VP Singh","year":"2014","unstructured":"Singh VP, et al. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18(1):1\u201314.","journal-title":"Korean J Physiol Pharmacol"},{"issue":"3","key":"3173_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.tem.2005.02.003","volume":"16","author":"G Giacchetti","year":"2005","unstructured":"Giacchetti G, et al. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16(3):120\u20136.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"3173_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/ki.2008.128","volume":"74","author":"JA Jefferson","year":"2008","unstructured":"Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008;74(1):22\u201336.","journal-title":"Kidney Int"},{"issue":"19","key":"3173_CR31","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco C, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3173_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/dbi20-0040","volume":"70","author":"KR Tuttle","year":"2021","unstructured":"Tuttle KR, et al. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Diabetes. 2021;70(1):1\u201316.","journal-title":"Diabetes"},{"key":"3173_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annu Rev Physiol. 2021;83:503\u201328.","journal-title":"Annu Rev Physiol"},{"key":"3173_CR34","doi-asserted-by":"publisher","first-page":"120543","DOI":"10.1016\/j.lfs.2022.120543","volume":"300","author":"X Lingli","year":"2022","unstructured":"Lingli X, Wenfang X. Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review. Life Sci. 2022;300:120543.","journal-title":"Life Sci"},{"issue":"1","key":"3173_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2215\/CJN.04010609","volume":"5","author":"R Santer","year":"2010","unstructured":"Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133\u201341.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"3173_CR36","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","volume":"61","author":"T Rieg","year":"2018","unstructured":"Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61(10):2079\u201386.","journal-title":"Diabetologia"},{"issue":"10","key":"3173_CR37","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.2337\/db13-0604","volume":"62","author":"MA Abdul-Ghani","year":"2013","unstructured":"Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30\u201350% of filtered glucose load in humans. Diabetes. 2013;62(10):3324\u20138.","journal-title":"Diabetes"},{"issue":"2","key":"3173_CR38","doi-asserted-by":"publisher","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang Y, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE. 2012;7(2):e30555.","journal-title":"PLoS ONE"},{"issue":"5","key":"3173_CR39","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner C, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512\u20137.","journal-title":"Nat Med"},{"key":"3173_CR40","doi-asserted-by":"crossref","unstructured":"Galicia-Garcia U et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci, 2020;21(17).","DOI":"10.3390\/ijms21176275"},{"issue":"1","key":"3173_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2337\/db18-0304","volume":"68","author":"BB Boland","year":"2019","unstructured":"Boland BB, et al. Pancreatic \u03b2-Cell Rest Replenishes Insulin Secretory Capacity and Attenuates Diabetes in an Extreme Model of Obese Type 2 Diabetes. Diabetes. 2019;68(1):131\u201340.","journal-title":"Diabetes"},{"issue":"12","key":"3173_CR42","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1210\/en.2019-00422","volume":"160","author":"Y Inaba","year":"2019","unstructured":"Inaba Y, et al. Hepatic Gluconeogenic Response to Single and Long-Term SGLT2 Inhibition in Lean\/Obese Male Hepatic G6pc-Reporter Mice. Endocrinology. 2019;160(12):2811\u201324.","journal-title":"Endocrinology"},{"issue":"3","key":"3173_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00125-019-05071-w","volume":"63","author":"J Shirakawa","year":"2020","unstructured":"Shirakawa J, et al. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia. 2020;63(3):577\u201387.","journal-title":"Diabetologia"},{"issue":"1 Pt 1","key":"3173_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lpm.2018.11.017","volume":"48","author":"A Vall\u00e9e","year":"2019","unstructured":"Vall\u00e9e A, Safar ME, Blacher J. Essential hypertension: Definitions, hemodynamic, clinical and therapeutic review]. Presse Med. 2019;48(1 Pt 1):19\u201328.","journal-title":"Presse Med"},{"key":"3173_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","volume":"94","author":"S Patel","year":"2017","unstructured":"Patel S, et al. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017;94:317\u201325.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"3173_CR46","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","volume":"116","author":"L Te Riet","year":"2015","unstructured":"Te Riet L, et al. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116(6):960\u201375.","journal-title":"Circ Res"},{"issue":"11","key":"3173_CR47","doi-asserted-by":"publisher","first-page":"e0165703","DOI":"10.1371\/journal.pone.0165703","volume":"11","author":"SJ Shin","year":"2016","unstructured":"Shin SJ, et al. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes. PLoS ONE. 2016;11(11):e0165703.","journal-title":"PLoS ONE"},{"key":"3173_CR48","doi-asserted-by":"crossref","unstructured":"Grillo A et al. Sodium Intake and Hypertension. Nutrients, 2019;11(9).","DOI":"10.3390\/nu11091970"},{"issue":"5","key":"3173_CR49","first-page":"712","volume":"36","author":"LJ DeLalio","year":"2020","unstructured":"DeLalio LJ, Sved AF, Stocker SD. Sympathetic Nervous System Contributions to Hypertension: Updates and Therapeutic Relevance. Can J Cardiol. 2020;36(5):712\u201320.","journal-title":"Can J Cardiol"},{"issue":"6","key":"3173_CR50","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41440-020-0410-8","volume":"43","author":"N Wan","year":"2020","unstructured":"Wan N, et al. Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease. Hypertens Res. 2020;43(6):492\u20139.","journal-title":"Hypertens Res"},{"key":"3173_CR51","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev.nutr.26.061505.111316","volume":"26","author":"KM O\u2019Shaughnessy","year":"2006","unstructured":"O\u2019Shaughnessy KM, Karet FE. Salt handling and hypertension. Annu Rev Nutr. 2006;26:343\u201365.","journal-title":"Annu Rev Nutr"},{"issue":"1","key":"3173_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","volume":"22","author":"CJ Bailey","year":"2022","unstructured":"Bailey CJ, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Curr Diab Rep. 2022;22(1):39\u201352.","journal-title":"Curr Diab Rep"},{"issue":"3","key":"3173_CR53","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ecl.2022.02.010","volume":"51","author":"A Chait","year":"2022","unstructured":"Chait A. Hypertriglyceridemia Endocrinol Metab Clin North Am. 2022;51(3):539\u201355.","journal-title":"Hypertriglyceridemia Endocrinol Metab Clin North Am"},{"issue":"1","key":"3173_CR54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12967-025-06171-5","volume":"23","author":"M Zhou","year":"2025","unstructured":"Zhou M, et al. Metabolic subtypes in hypertriglyceridemia and associations with diseases: insights from population-based metabolome atlas. J Transl Med. 2025;23(1):256.","journal-title":"J Transl Med"},{"key":"3173_CR55","doi-asserted-by":"crossref","unstructured":"Nasiri-Ansari N et al. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE((-\/-)) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. Int J Mol Sci, 2021;22(2).","DOI":"10.3390\/ijms22020818"},{"key":"3173_CR56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3389\/fendo.2020.00252","volume":"11","author":"CJ Packard","year":"2020","unstructured":"Packard CJ, Boren J, Taskinen MR. Causes and Consequences of Hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:252.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"3173_CR57","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","volume":"38","author":"D Basu","year":"2018","unstructured":"Basu D, et al. Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition. Arterioscler Thromb Vasc Biol. 2018;38(9):2207\u201316.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"3173_CR58","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2337\/db16-1410","volume":"66","author":"TP O\u2019Brien","year":"2017","unstructured":"O\u2019Brien TP, et al. Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle. Diabetes. 2017;66(5):1172\u201384.","journal-title":"Diabetes"},{"issue":"3","key":"3173_CR59","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/nu5030981","volume":"5","author":"A Brahm","year":"2013","unstructured":"Brahm A, Hegele RA. Hypertriglyceridemia Nutrients. 2013;5(3):981\u20131001.","journal-title":"Hypertriglyceridemia Nutrients"},{"issue":"2","key":"3173_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","volume":"20","author":"MG Saklayen","year":"2018","unstructured":"Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12.","journal-title":"Curr Hypertens Rep"},{"issue":"9468","key":"3173_CR61","first-page":"1415","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome Lancet. 2005;365(9468):1415\u201328.","journal-title":"The metabolic syndrome Lancet"},{"issue":"1","key":"3173_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI92035","volume":"127","author":"AR Saltiel","year":"2017","unstructured":"Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1\u20134.","journal-title":"J Clin Invest"},{"key":"3173_CR63","doi-asserted-by":"publisher","first-page":"113677","DOI":"10.1016\/j.bcp.2019.113677","volume":"170","author":"A Arag\u00f3n-Herrera","year":"2019","unstructured":"Arag\u00f3n-Herrera A, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170:113677.","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"3173_CR64","doi-asserted-by":"publisher","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","volume":"9","author":"M Oelze","year":"2014","unstructured":"Oelze M, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE. 2014;9(11):e112394.","journal-title":"PLoS ONE"},{"issue":"10","key":"3173_CR65","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1016\/j.immuni.2025.09.011","volume":"58","author":"MY Donath","year":"2025","unstructured":"Donath MY, Drucker DJ. Obesity, diabetes, and inflammation: Pathophysiology and clinical implications. Immunity. 2025;58(10):2373\u201382.","journal-title":"Immunity"},{"key":"3173_CR66","doi-asserted-by":"crossref","unstructured":"Kearney J, Gnudi L. The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes. Pharmaceutics, 2023;15(5).","DOI":"10.3390\/pharmaceutics15051343"},{"key":"3173_CR67","doi-asserted-by":"publisher","first-page":"111315","DOI":"10.1016\/j.biopha.2021.111315","volume":"137","author":"B Ahmed","year":"2021","unstructured":"Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315.","journal-title":"Biomed Pharmacother"},{"key":"3173_CR68","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"L Xu","year":"2017","unstructured":"Xu L, et al. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. EBioMedicine. 2017;20:137\u201349.","journal-title":"EBioMedicine"},{"issue":"2","key":"3173_CR69","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s42255-018-0021-8","volume":"1","author":"ET Chouchani","year":"2019","unstructured":"Chouchani ET, Kajimura S. Metabolic adaptation and maladaptation in adipose tissue. Nat Metab. 2019;1(2):189\u2013200.","journal-title":"Nat Metab"},{"issue":"7","key":"3173_CR70","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/oby.23771","volume":"31","author":"M Kabir","year":"2023","unstructured":"Kabir M, et al. Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin-resistant canine model. Obes (Silver Spring). 2023;31(7):1798\u2013811.","journal-title":"Obes (Silver Spring)"},{"key":"3173_CR71","doi-asserted-by":"publisher","first-page":"745058","DOI":"10.3389\/fphys.2021.745058","volume":"12","author":"L Xu","year":"2021","unstructured":"Xu L, et al. Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay\/J Mice and Mouse Adipocytes. Front Physiol. 2021;12:745058.","journal-title":"Front Physiol"},{"key":"3173_CR72","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol, 2024;81(3):492\u2013542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"3173_CR73","doi-asserted-by":"publisher","first-page":"155664","DOI":"10.1016\/j.metabol.2023.155664","volume":"147","author":"M Kokkorakis","year":"2023","unstructured":"Kokkorakis M, et al. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need. Metabolism. 2023;147:155664.","journal-title":"Metabolism"},{"key":"3173_CR74","doi-asserted-by":"crossref","unstructured":"Yanai H et al. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int J Mol Sci, 2023;24(20).","DOI":"10.3390\/ijms242015473"},{"issue":"4","key":"3173_CR75","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702.","journal-title":"Gut"},{"key":"3173_CR76","doi-asserted-by":"crossref","unstructured":"Radu F et al. The Link between NAFLD and Metabolic Syndrome. Diagnostics (Basel), 2023;13(4).","DOI":"10.3390\/diagnostics13040614"},{"key":"3173_CR77","doi-asserted-by":"publisher","first-page":"110539","DOI":"10.1016\/j.mce.2019.110539","volume":"498","author":"TI Petito-da-Silva","year":"2019","unstructured":"Petito-da-Silva TI, Souza-Mello V, Barbosa-da-Silva S. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress. Mol Cell Endocrinol. 2019;498:110539.","journal-title":"Mol Cell Endocrinol"},{"issue":"1\u20133","key":"3173_CR78","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara A, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1\u20133):246\u201355.","journal-title":"Eur J Pharmacol"},{"key":"3173_CR79","doi-asserted-by":"crossref","unstructured":"Bishr A, El-Mokadem BM, Gomaa AA. Canagliflozin alleviates acetaminophen-induced renal and hepatic injury in mice by modulating the p-GSK3\u03b2\/Fyn-kinase\/Nrf-2 and p-AMPK-\u03b1\/STAT-3\/SOCS-3 pathways. Sci Rep, 2025;15(1):729.","DOI":"10.1038\/s41598-024-82163-7"},{"key":"3173_CR80","doi-asserted-by":"publisher","first-page":"107492","DOI":"10.1016\/j.intimp.2021.107492","volume":"94","author":"Z Meng","year":"2021","unstructured":"Meng Z, et al. The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway. Int Immunopharmacol. 2021;94:107492.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3173_CR81","doi-asserted-by":"publisher","first-page":"e0146337","DOI":"10.1371\/journal.pone.0146337","volume":"11","author":"Y Honda","year":"2016","unstructured":"Honda Y, et al. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS ONE. 2016;11(1):e0146337.","journal-title":"PLoS ONE"},{"key":"3173_CR82","doi-asserted-by":"publisher","first-page":"155657","DOI":"10.1016\/j.metabol.2023.155657","volume":"146","author":"Y Shen","year":"2023","unstructured":"Shen Y, et al. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis. Metabolism. 2023;146:155657.","journal-title":"Metabolism"},{"key":"3173_CR83","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","volume":"121","author":"T Higashi","year":"2017","unstructured":"Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121:27\u201342.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3173_CR84","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/gutjnl-2024-332687","volume":"74","author":"S Bea","year":"2025","unstructured":"Bea S, et al. Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2025;74(2):284\u201394.","journal-title":"Gut"},{"issue":"9","key":"3173_CR85","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, et al. Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. Diabetes Care. 2022;45(9):2064\u201375.","journal-title":"Diabetes Care"},{"issue":"4","key":"3173_CR86","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1111\/eci.70003","volume":"55","author":"LAM Konings","year":"2025","unstructured":"Konings LAM, et al. Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review. Eur J Clin Invest. 2025;55(4):e70003.","journal-title":"Eur J Clin Invest"},{"key":"3173_CR87","doi-asserted-by":"publisher","first-page":"107647","DOI":"10.1016\/j.phrs.2025.107647","volume":"213","author":"H Li","year":"2025","unstructured":"Li H, et al. The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Pharmacol Res. 2025;213:107647.","journal-title":"Pharmacol Res"},{"issue":"6","key":"3173_CR88","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","volume":"16","author":"V Vallon","year":"2020","unstructured":"Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16(6):317\u201336.","journal-title":"Nat Rev Nephrol"},{"key":"3173_CR89","doi-asserted-by":"publisher","first-page":"113801","DOI":"10.1016\/j.biopha.2022.113801","volume":"156","author":"S Dey","year":"2022","unstructured":"Dey S, et al. Multifaceted entrancing role of glucose and its analogue, 2-deoxy-D-glucose in cancer cell proliferation, inflammation, and virus infection. Biomed Pharmacother. 2022;156:113801.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"3173_CR90","doi-asserted-by":"publisher","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","volume":"8","author":"U Panchapakesan","year":"2013","unstructured":"Panchapakesan U, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells\u2013renoprotection in diabetic nephropathy? PLoS ONE. 2013;8(2):e54442.","journal-title":"PLoS ONE"},{"issue":"6","key":"3173_CR91","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1681\/ASN.2020040423","volume":"32","author":"T Zehra","year":"2021","unstructured":"Zehra T, Cupples WA, Braam B. Tubuloglomerular Feedback Synchronization in Nephrovascular Networks. J Am Soc Nephrol. 2021;32(6):1293\u2013304.","journal-title":"J Am Soc Nephrol"},{"issue":"Supplement1","key":"3173_CR92","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","volume":"40","author":"RZ Alicic","year":"2025","unstructured":"Alicic RZ, Neumiller JJ, Tuttle KR. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease. Nephrol Dial Transpl. 2025;40(Supplement1):i3\u201317.","journal-title":"Nephrol Dial Transpl"},{"issue":"8","key":"3173_CR93","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1161\/HYPERTENSIONAHA.123.21505","volume":"80","author":"J Wu","year":"2023","unstructured":"Wu J. Paradigm Shift in Hyperglycemic Glomerular Hyperfiltration: Blunted Tubuloglomerular Feedback or Preglomerular Vasodilation? Hypertension. 2023;80(8):1611\u20133.","journal-title":"Hypertension"},{"key":"3173_CR94","doi-asserted-by":"crossref","unstructured":"Blazek O, Bakris GL. Slowing Progression Diabet Kidney Disease Cells, 2023;12(15).","DOI":"10.3390\/cells12151975"},{"issue":"2","key":"3173_CR95","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jchf.2018.11.013","volume":"7","author":"O Vardeny","year":"2019","unstructured":"Vardeny O, Vaduganathan M. Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. JACC Heart Fail. 2019;7(2):169\u201372.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"3173_CR96","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11892-020-01347-3","volume":"20","author":"MS Khan","year":"2020","unstructured":"Khan MS, Vaduganathan M. What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure? Curr Diab Rep. 2020;20(11):63.","journal-title":"Curr Diab Rep"},{"issue":"10","key":"3173_CR97","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"key":"3173_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2024.09.009","volume":"132","author":"E Gronda","year":"2025","unstructured":"Gronda E, et al. Gliflozines use in heart failure patients. Focus on renal actions and overview of clinical experience. Eur J Intern Med. 2025;132:1\u20138.","journal-title":"Eur J Intern Med"},{"issue":"21","key":"3173_CR99","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"3173_CR100","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"7","key":"3173_CR101","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","volume":"8","author":"DZI Cherney","year":"2020","unstructured":"Cherney DZI, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8(7):582\u201393.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"3173_CR102","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"3173_CR103","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon V, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22(1):104\u201312.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"3173_CR104","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","volume":"61","author":"C Ghezzi","year":"2018","unstructured":"Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018;61(10):2087\u201397.","journal-title":"Diabetologia"},{"issue":"13","key":"3173_CR105","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","volume":"292","author":"XX Wang","year":"2017","unstructured":"Wang XX, et al. SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 Protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem. 2017;292(13):5335\u201348.","journal-title":"J Biol Chem"},{"issue":"2","key":"3173_CR106","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"V Vallon","year":"2014","unstructured":"Vallon V, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Ren Physiol. 2014;306(2):F194\u2013204.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"11","key":"3173_CR107","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","volume":"149","author":"AM Billing","year":"2024","unstructured":"Billing AM, et al. Metabolic Communication by SGLT2 Inhibition. Circulation. 2024;149(11):860\u201384.","journal-title":"Circulation"},{"issue":"10","key":"3173_CR108","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1440-1681.2006.04475.x","volume":"33","author":"PM O\u2019Connor","year":"2006","unstructured":"O\u2019Connor PM. Renal oxygen delivery: matching delivery to metabolic demand. Clin Exp Pharmacol Physiol. 2006;33(10):961\u20137.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"3173_CR109","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fphys.2017.00385","volume":"8","author":"ZZ Liu","year":"2017","unstructured":"Liu ZZ, et al. Renal Oxygenation in the Pathophysiology of Chronic Kidney Disease. Front Physiol. 2017;8:385.","journal-title":"Front Physiol"},{"issue":"11","key":"3173_CR110","doi-asserted-by":"publisher","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","volume":"310","author":"AT Layton","year":"2016","unstructured":"Layton AT, Vallon V, Edwards A. Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Ren Physiol. 2016;310(11):F1269\u201383.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"Supplement1","key":"3173_CR111","doi-asserted-by":"publisher","first-page":"i18","DOI":"10.1093\/ndt\/gfae211","volume":"40","author":"CA Wagner","year":"2025","unstructured":"Wagner CA. Beyond SGLT2: proximal tubule transporters as potential drug targets for chronic kidney disease. Nephrol Dial Transpl. 2025;40(Supplement1):i18\u201328.","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"3173_CR112","doi-asserted-by":"publisher","first-page":"F1343","DOI":"10.1152\/ajprenal.00007.2015","volume":"308","author":"AT Layton","year":"2015","unstructured":"Layton AT, Vallon V, Edwards A. Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. Am J Physiol Ren Physiol. 2015;308(12):F1343\u201357.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"9","key":"3173_CR113","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"3173_CR114","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","volume":"309","author":"J O\u2019Neill","year":"2015","unstructured":"O\u2019Neill J, et al. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Ren Physiol. 2015;309(3):F227\u201334.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"5","key":"3173_CR115","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","volume":"66","author":"S Gullaksen","year":"2023","unstructured":"Gullaksen S, et al. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial. Diabetologia. 2023;66(5):813\u201325.","journal-title":"Diabetologia"},{"issue":"48","key":"3173_CR116","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","volume":"44","author":"M Packer","year":"2023","unstructured":"Packer M. Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors. Eur Heart J. 2023;44(48):5027\u201335.","journal-title":"Eur Heart J"},{"issue":"17","key":"3173_CR117","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation. 2019;139(17):1985\u20137.","journal-title":"Circulation"},{"issue":"5","key":"3173_CR118","doi-asserted-by":"publisher","first-page":"E621","DOI":"10.1152\/ajpendo.00277.2023","volume":"325","author":"SN Heyman","year":"2023","unstructured":"Heyman SN, et al. Novel perspectives regarding the physiologic mechanisms by which gliflozins induce reticulocytosis and erythrocytosis. Am J Physiol Endocrinol Metab. 2023;325(5):E621\u20133.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3173_CR119","doi-asserted-by":"crossref","unstructured":"Trnovska J et al. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress. Int J Mol Sci, 2021;22(19).","DOI":"10.3390\/ijms221910606"},{"key":"3173_CR120","doi-asserted-by":"publisher","first-page":"109506","DOI":"10.1016\/j.cellsig.2019.109506","volume":"68","author":"NA Das","year":"2020","unstructured":"Das NA, et al. Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition. Cell Signal. 2020;68:109506.","journal-title":"Cell Signal"},{"key":"3173_CR121","doi-asserted-by":"crossref","unstructured":"Pirklbauer M et al. Empagliflozin Inhibits IL-1\u03b2-Mediated Inflammatory Response in Human Proximal Tubular Cells. Int J Mol Sci, 2021;22(10).","DOI":"10.3390\/ijms22105089"},{"key":"3173_CR122","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","volume":"243","author":"A Di Franco","year":"2017","unstructured":"Di Franco A, et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. Int J Cardiol. 2017;243:86\u201390.","journal-title":"Int J Cardiol"},{"key":"3173_CR123","doi-asserted-by":"publisher","first-page":"116505","DOI":"10.1016\/j.biopha.2024.116505","volume":"174","author":"X Chen","year":"2024","unstructured":"Chen X, et al. Canagliflozin inhibits PASMCs proliferation via regulating SGLT1\/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension. Biomed Pharmacother. 2024;174:116505.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"3173_CR124","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10557-021-07190-2","volume":"36","author":"VG Yerra","year":"2022","unstructured":"Yerra VG, et al. Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy. Cardiovasc Drugs Ther. 2022;36(4):619\u201332.","journal-title":"Cardiovasc Drugs Ther"},{"key":"3173_CR125","doi-asserted-by":"publisher","first-page":"103010","DOI":"10.1016\/j.redox.2023.103010","volume":"69","author":"W Cai","year":"2024","unstructured":"Cai W, et al. Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. Redox Biol. 2024;69:103010.","journal-title":"Redox Biol"},{"key":"3173_CR126","doi-asserted-by":"publisher","first-page":"1005408","DOI":"10.3389\/fcvm.2023.1005408","volume":"10","author":"T Koizumi","year":"2023","unstructured":"Koizumi T, et al. Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats. Front Cardiovasc Med. 2023;10:1005408.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"3173_CR127","doi-asserted-by":"publisher","first-page":"e006277","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","volume":"13","author":"NJ Byrne","year":"2020","unstructured":"Byrne NJ, et al. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure. Circ Heart Fail. 2020;13(1):e006277.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"3173_CR128","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1751-7133.2008.07210.x","volume":"14","author":"H Ooi","year":"2008","unstructured":"Ooi H, Chung W, Biolo A. Arterial stiffness and vascular load in heart failure. Congest Heart Fail. 2008;14(1):31\u20136.","journal-title":"Congest Heart Fail"},{"issue":"2173","key":"3173_CR129","first-page":"20190342","volume":"378","author":"L Marx","year":"2020","unstructured":"Marx L, et al. Personalization of electro-mechanical models of the pressure-overloaded left ventricle: fitting of Windkessel-type afterload models. Philos Trans Math Phys Eng Sci. 2020;378(2173):20190342.","journal-title":"Philos Trans Math Phys Eng Sci"},{"key":"3173_CR130","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fphar.2018.00241","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension. Front Pharmacol. 2018;9:241.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3173_CR131","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10741-017-9600-0","volume":"22","author":"MJ Pearson","year":"2017","unstructured":"Pearson MJ, Mungovan SF, Smart NA. Effect of exercise on diastolic function in heart failure patients: a systematic review and meta-analysis. Heart Fail Rev. 2017;22(2):229\u201342.","journal-title":"Heart Fail Rev"},{"issue":"8","key":"3173_CR132","doi-asserted-by":"publisher","first-page":"165807","DOI":"10.1016\/j.bbadis.2020.165807","volume":"1866","author":"J Moellmann","year":"2020","unstructured":"Moellmann J, et al. Empagliflozin improves left ventricular diastolic function of db\/db mice. Biochim Biophys Acta Mol Basis Dis. 2020;1866(8):165807.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"3173_CR133","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","volume":"14","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, et al. Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis\/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. JACC Cardiovasc Imaging. 2021;14(2):393\u2013407.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"3173_CR134","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","volume":"136","author":"M Packer","year":"2017","unstructured":"Packer M. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure. Circulation. 2017;136(16):1548\u201359.","journal-title":"Circulation"},{"issue":"3","key":"3173_CR135","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0095-4543(05)70167-6","volume":"27","author":"PTJ Pollard","year":"2000","unstructured":"Pollard P T.J. The acute myocardial infarction. Prim Care. 2000;27(3):631\u201349. vi.","journal-title":"Prim Care"},{"issue":"1","key":"3173_CR136","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12933-022-01655-w","volume":"21","author":"M Baviera","year":"2022","unstructured":"Baviera M, et al. Diabetes mellitus duration and mortality in patients hospitalized with acute myocardial infarction. Cardiovasc Diabetol. 2022;21(1):223.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3173_CR137","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12933-023-01758-y","volume":"22","author":"F Trombara","year":"2023","unstructured":"Trombara F, et al. Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction. Cardiovasc Diabetol. 2023;22(1):26.","journal-title":"Cardiovasc Diabetol"},{"key":"3173_CR138","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","volume":"8","author":"I Andreadou","year":"2017","unstructured":"Andreadou I, et al. Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects. Front Physiol. 2017;8:1077.","journal-title":"Front Physiol"},{"issue":"5","key":"3173_CR139","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1002\/ehf2.13509","volume":"8","author":"K Mozawa","year":"2021","unstructured":"Mozawa K, et al. Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus. ESC Heart Fail. 2021;8(5):4161\u201373.","journal-title":"ESC Heart Fail"},{"key":"3173_CR140","doi-asserted-by":"publisher","first-page":"1594861","DOI":"10.3389\/fendo.2025.1594861","volume":"16","author":"S Li","year":"2025","unstructured":"Li S, et al. Dapagliflozin improves cardiac function and reduces adverse events in myocardial infarction: a meta-analysis in diabetic and non-diabetic populations. Front Endocrinol (Lausanne). 2025;16:1594861.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3173_CR141","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.hrtlng.2025.05.010","volume":"73","author":"H Li","year":"2025","unstructured":"Li H, et al. Effect of SGLT2 inhibitors on inflammatory markers and oxygen consumption in non-diabetic patients with STEMI undergoing primary PCI: A parallel design single blind controlled trial. Heart Lung. 2025;73:174\u20139.","journal-title":"Heart Lung"},{"key":"3173_CR142","doi-asserted-by":"crossref","unstructured":"Badimon JJ, Requena-Ibanez JA, Picatoste B, Fardman B, Ishikawa K, Mazurek R, Pieper M, Fuster V. Cardioprotective effect of empagliflozin in acute myocardial infarction: the role of ketone bodies availability. Eur Heart J, 2022.","DOI":"10.1093\/eurheartj\/ehac544.1372"},{"issue":"10","key":"3173_CR143","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/cvr\/cvad100","volume":"119","author":"L Da Dalt","year":"2023","unstructured":"Da Dalt L, et al. Cardiac lipid metabolism, mitochondrial function, and heart failure. Cardiovasc Res. 2023;119(10):1905\u201314.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"3173_CR144","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.tem.2021.07.006","volume":"32","author":"SR Yurista","year":"2021","unstructured":"Yurista SR, et al. Ketone bodies for the failing heart: fuels that can fix the engine? Trends Endocrinol Metab. 2021;32(10):814\u201326.","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"3173_CR145","doi-asserted-by":"publisher","first-page":"e018298","DOI":"10.1161\/JAHA.120.018298","volume":"10","author":"X Li","year":"2021","unstructured":"Li X, et al. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure. J Am Heart Assoc. 2021;10(6):e018298.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"3173_CR146","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13098-023-01061-6","volume":"15","author":"L Zhang","year":"2023","unstructured":"Zhang L, et al. Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR\/p-ULK1 signaling pathway-mediated autophagy. Diabetol Metab Syndr. 2023;15(1):93.","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"3173_CR147","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ejhf.1320","volume":"21","author":"A van der Pol","year":"2019","unstructured":"van der Pol A, et al. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail. 2019;21(4):425\u201335.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"3173_CR148","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15.","journal-title":"Cardiovasc Diabetol"},{"key":"3173_CR149","doi-asserted-by":"crossref","unstructured":"Lafuse WP, Wozniak DJ, Rajaram MVS. Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair. Cells, 2020;10(1).","DOI":"10.3390\/cells10010051"},{"issue":"15","key":"3173_CR150","first-page":"7794","volume":"15","author":"XZ Zou","year":"2023","unstructured":"Zou XZ, Hao JF, Hou MX. Hmgcs2 regulates M2 polarization of macrophages to repair myocardial injury induced by sepsis. Aging. 2023;15(15):7794\u2013810.","journal-title":"Aging"},{"key":"3173_CR151","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.redox.2015.01.008","volume":"4","author":"A Abderrazak","year":"2015","unstructured":"Abderrazak A, et al. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 2015;4:296\u2013307.","journal-title":"Redox Biol"},{"issue":"2","key":"3173_CR152","doi-asserted-by":"publisher","first-page":"S314","DOI":"10.2337\/dc09-S330","volume":"32","author":"D Versari","year":"2009","unstructured":"Versari D, et al. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009;32(2):S314\u201321.","journal-title":"Diabetes Care"},{"key":"3173_CR153","doi-asserted-by":"publisher","first-page":"102979","DOI":"10.1016\/j.redox.2023.102979","volume":"69","author":"X Li","year":"2024","unstructured":"Li X, et al. Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE\/PKC\/NOX axis. Redox Biol. 2024;69:102979.","journal-title":"Redox Biol"},{"issue":"1","key":"3173_CR154","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12933-020-00997-7","volume":"19","author":"SH Park","year":"2020","unstructured":"Park SH, et al. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovasc Diabetol. 2020;19(1):19.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"3173_CR155","doi-asserted-by":"publisher","first-page":"e19152","DOI":"10.1016\/j.heliyon.2023.e19152","volume":"9","author":"S Tai","year":"2023","unstructured":"Tai S, et al. Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes. Heliyon. 2023;9(8):e19152.","journal-title":"Heliyon"},{"key":"3173_CR156","doi-asserted-by":"crossref","unstructured":"Leclercq F. [Anatomy and physiology of the heart and coronary arteries]. Soins, 2015(793):28\u201331.","DOI":"10.1016\/j.soin.2015.01.017"},{"key":"3173_CR157","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/DMSO.S419125","volume":"17","author":"Q Kong","year":"2024","unstructured":"Kong Q, et al. Empagliflozin Induces Vascular Relaxation in Rat Coronary Artery Due to Activation of BK Channels. Diabetes Metab Syndr Obes. 2024;17:247\u201357.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"3173_CR158","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","volume":"18","author":"DD Adingupu","year":"2019","unstructured":"Adingupu DD, et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob(-\/-) mice. Cardiovasc Diabetol. 2019;18(1):16.","journal-title":"Cardiovasc Diabetol"},{"key":"3173_CR159","doi-asserted-by":"crossref","unstructured":"Weinberg Sibony R et al. Drug Therapies for Diabetes. Int J Mol Sci, 2023;24(24).","DOI":"10.3390\/ijms242417147"},{"issue":"3","key":"3173_CR160","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","volume":"335","author":"BL Neuen","year":"2026","unstructured":"Neuen BL, et al. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis. JAMA. 2026;335(3):233\u201344.","journal-title":"JAMA"},{"issue":"7","key":"3173_CR161","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12(7):447\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"3173_CR162","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"5","key":"3173_CR163","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102(5):990\u20139.","journal-title":"Kidney Int"},{"issue":"2","key":"3173_CR164","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","volume":"5","author":"KM Talha","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. Int J Heart Fail. 2023;5(2):82\u201390.","journal-title":"Int J Heart Fail"},{"issue":"4","key":"3173_CR165","first-page":"170","volume":"1","author":"MA Leddy","year":"2008","unstructured":"Leddy MA, Power ML, Schulkin J. The impact of maternal obesity on maternal and fetal health. Rev Obstet Gynecol. 2008;1(4):170\u20138.","journal-title":"Rev Obstet Gynecol"},{"issue":"7","key":"3173_CR166","first-page":"pCd001871","volume":"7","author":"T Brown","year":"2019","unstructured":"Brown T, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev. 2019;7(7):pCd001871.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"3173_CR167","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2174\/0929867326666190124121725","volume":"27","author":"S Paccosi","year":"2020","unstructured":"Paccosi S, et al. Obesity Therapy: How and Why? Curr Med Chem. 2020;27(2):174\u201386.","journal-title":"Curr Med Chem"},{"issue":"Suppl 2","key":"3173_CR168","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","volume":"27","author":"RW Thomsen","year":"2025","unstructured":"Thomsen RW, et al. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27(Suppl 2):66\u201388.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"3173_CR169","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/apt.14956","volume":"48","author":"F Ca\u00f1ete","year":"2018","unstructured":"Ca\u00f1ete F, et al. Review article: the relationship between obesity, bariatric surgery, and inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(8):807\u201316.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3173_CR170","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.12578","volume":"18","author":"SP Rajeev","year":"2016","unstructured":"Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes Metab. 2016;18(2):125\u201334.","journal-title":"Diabetes Obes Metab"},{"key":"3173_CR171","doi-asserted-by":"crossref","unstructured":"Szekeres Z et al. Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. Int J Mol Sci, 2023;24(5).","DOI":"10.3390\/ijms24054405"},{"issue":"11","key":"3173_CR172","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1089\/dia.2017.0134","volume":"19","author":"RE Brown","year":"2017","unstructured":"Brown RE, Gupta N, Aronson R. Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis. Diabetes Technol Ther. 2017;19(11):685\u201391.","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"3173_CR173","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/oby.22066","volume":"26","author":"X Cai","year":"2018","unstructured":"Cai X, et al. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obes (Silver Spring). 2018;26(1):70\u201380.","journal-title":"Obes (Silver Spring)"},{"issue":"3\u20134","key":"3173_CR174","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00508-022-02096-x","volume":"135","author":"M S\u00e4emann","year":"2023","unstructured":"S\u00e4emann M, et al. Value of SGLT-2 inhibitors in the treatment of chronic kidney disease: Clinical and practical implications. Wien Klin Wochenschr. 2023;135(3\u20134):97\u2013109.","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"3173_CR175","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/jcm3020595","volume":"3","author":"G Goswami","year":"2014","unstructured":"Goswami G, Shinkazh N, Davis N. Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. J Clin Med. 2014;3(2):595\u2013613.","journal-title":"J Clin Med"},{"key":"3173_CR176","doi-asserted-by":"crossref","unstructured":"Androutsakos T et al. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci, 2022;23(6).","DOI":"10.3390\/ijms23063107"},{"issue":"3","key":"3173_CR177","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","volume":"21","author":"R P\u00e1lsson","year":"2014","unstructured":"P\u00e1lsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):273\u201380.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"3173_CR178","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jchf.2020.09.006","volume":"9","author":"M Khayyat-Kholghi","year":"2021","unstructured":"Khayyat-Kholghi M, et al. Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study. JACC Heart Fail. 2021;9(2):100\u201311.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"3173_CR179","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1055\/a-1163-7590","volume":"145","author":"GH Heine","year":"2020","unstructured":"Heine GH. [Antidiabetic SGLT-2 inhibitors prevent progression of chronic kidney disease]. Dtsch Med Wochenschr. 2020;145(11):762\u20136.","journal-title":"Dtsch Med Wochenschr"},{"issue":"17","key":"3173_CR180","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","volume":"142","author":"J Rangaswami","year":"2020","unstructured":"Rangaswami J, et al. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation. 2020;142(17):e265\u201386.","journal-title":"Circulation"},{"issue":"5","key":"3173_CR181","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/dom.14657","volume":"24","author":"JJ Rhee","year":"2022","unstructured":"Rhee JJ, et al. Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease. Diabetes Obes Metab. 2022;24(5):928\u201337.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"3173_CR182","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"11","key":"3173_CR183","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","volume":"139","author":"D Fitchett","year":"2019","unstructured":"Fitchett D, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019;139(11):1384\u201395.","journal-title":"Circulation"},{"key":"3173_CR184","unstructured":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol, 2024;12(1): 39\u201350."},{"key":"3173_CR185","unstructured":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol, 2024;12(1):51\u201360."},{"issue":"1","key":"3173_CR186","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3173_CR187","unstructured":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet, 2022;400(10365):1788\u2013801."},{"issue":"4","key":"3173_CR188","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/dom.15427","volume":"26","author":"JJ Rhee","year":"2024","unstructured":"Rhee JJ, et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild\/moderate chronic kidney disease. Diabetes Obes Metab. 2024;26(4):1273\u201381.","journal-title":"Diabetes Obes Metab"},{"key":"3173_CR189","doi-asserted-by":"publisher","first-page":"110161","DOI":"10.1016\/j.diabres.2022.110161","volume":"194","author":"S Tsukamoto","year":"2022","unstructured":"Tsukamoto S, et al. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. Diabetes Res Clin Pract. 2022;194:110161.","journal-title":"Diabetes Res Clin Pract"},{"issue":"432","key":"3173_CR190","first-page":"p487","volume":"2020","author":"JB Buse","year":"2019","unstructured":"Buse J.B., et al. Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2019;2020(432):p487\u2013493.","journal-title":"Diabetes Care"},{"issue":"9","key":"3173_CR191","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41440-020-0491-4","volume":"43","author":"T Masuda","year":"2020","unstructured":"Masuda T, Nagata D. Recent advances in the management of secondary hypertension: chronic kidney disease. Hypertens Res. 2020;43(9):869\u201375.","journal-title":"Hypertens Res"},{"issue":"5","key":"3173_CR192","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/dom.14639","volume":"24","author":"M Antlanger","year":"2022","unstructured":"Antlanger M, et al. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial. Diabetes Obes Metab. 2022;24(5):816\u201326.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"3173_CR193","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136(3):249\u201359.","journal-title":"Circulation"},{"issue":"1","key":"3173_CR194","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12872-023-03324-6","volume":"23","author":"YL Huang","year":"2023","unstructured":"Huang YL, et al. Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis. BMC Cardiovasc Disord. 2023;23(1):293.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"3173_CR195","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40256-020-00397-y","volume":"20","author":"J Reid","year":"2020","unstructured":"Reid J, et al. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention. Am J Cardiovasc Drugs. 2020;20(5):419\u201329.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"8","key":"3173_CR196","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/1753-0407.13405","volume":"15","author":"J Wang","year":"2023","unstructured":"Wang J, et al. Effects of first-line antidiabetic drugs on the improvement of arterial stiffness: A Bayesian network meta-analysis. J Diabetes. 2023;15(8):685\u201398.","journal-title":"J Diabetes"},{"issue":"2","key":"3173_CR197","doi-asserted-by":"publisher","first-page":"2304667","DOI":"10.1080\/07853890.2024.2304667","volume":"55","author":"P Stachteas","year":"2023","unstructured":"Stachteas P, et al. The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis. Ann Med. 2023;55(2):2304667.","journal-title":"Ann Med"},{"issue":"2","key":"3173_CR198","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358.","journal-title":"JAMA Cardiol"},{"key":"3173_CR199","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejim.2021.03.020","volume":"87","author":"Y Lu","year":"2021","unstructured":"Lu Y, et al. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials. Eur J Intern Med. 2021;87:20\u20138.","journal-title":"Eur J Intern Med"},{"key":"3173_CR200","doi-asserted-by":"publisher","first-page":"n1091","DOI":"10.1136\/bmj.n1091","volume":"373","author":"S Li","year":"2021","unstructured":"Li S, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021;373:n1091.","journal-title":"BMJ"},{"issue":"16","key":"3173_CR201","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"11","key":"3173_CR202","doi-asserted-by":"publisher","first-page":"e011980","DOI":"10.1161\/CIRCHEARTFAILURE.124.011980","volume":"17","author":"S Selvaraj","year":"2024","unstructured":"Selvaraj S, et al. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circ Heart Fail. 2024;17(11):e011980.","journal-title":"Circ Heart Fail"},{"issue":"3","key":"3173_CR203","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374.","journal-title":"Nat Med"},{"issue":"11","key":"3173_CR204","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360.","journal-title":"Nat Med"},{"issue":"4","key":"3173_CR205","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021;143(4):326\u201336.","journal-title":"Circulation"},{"issue":"14","key":"3173_CR206","first-page":"1304","volume":"46","author":"M B\u00f6hm","year":"2025","unstructured":"B\u00f6hm M, et al. Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J. 2025;46(14):1304\u201317.","journal-title":"Eur Heart J"},{"key":"3173_CR207","doi-asserted-by":"crossref","unstructured":"Huang Z, et al. Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial. ESC Heart Fail; 2025.","DOI":"10.1002\/ehf2.15296"},{"issue":"2","key":"3173_CR208","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s12325-021-01989-z","volume":"39","author":"S Rao","year":"2022","unstructured":"Rao S. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Adv Ther. 2022;39(2):845\u201361.","journal-title":"Adv Ther"},{"issue":"36","key":"3173_CR209","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"5","key":"3173_CR210","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s13300-019-0657-8","volume":"10","author":"A Ali","year":"2019","unstructured":"Ali A, et al. SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. Diabetes Ther. 2019;10(5):1595\u2013622.","journal-title":"Diabetes Ther"},{"issue":"34","key":"3173_CR211","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"key":"3173_CR212","doi-asserted-by":"publisher","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","volume":"381","author":"Q Shi","year":"2023","unstructured":"Shi Q, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068.","journal-title":"BMJ"},{"key":"3173_CR213","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ahj.2024.12.006","volume":"282","author":"AJ Nelson","year":"2025","unstructured":"Nelson AJ, et al. Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics. Am Heart J. 2025;282:51\u20137.","journal-title":"Am Heart J"},{"issue":"3","key":"3173_CR214","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","volume":"103","author":"S Geerlings","year":"2014","unstructured":"Geerlings S, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373\u201381.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"3173_CR215","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","volume":"27","author":"KM Johnsson","year":"2013","unstructured":"Johnsson KM, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27(5):479\u201384.","journal-title":"J Diabetes Complications"},{"issue":"10","key":"3173_CR216","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"key":"3173_CR217","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573.","journal-title":"BMJ"},{"issue":"1","key":"3173_CR218","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","volume":"7","author":"J Liu","year":"2017","unstructured":"Liu J, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824.","journal-title":"Sci Rep"},{"key":"3173_CR219","doi-asserted-by":"crossref","unstructured":"Nardi G et al. Contrast-Induced Acute Kidney Injury in Patients with Heart Failure on Sodium-Glucose Cotransporter-2 Inhibitors Undergoing Radiocontrast Agent Invasive Procedures: A Propensity-Matched Analysis. J Clin Med, 2024. 13(7).","DOI":"10.3390\/jcm13072041"},{"key":"3173_CR220","doi-asserted-by":"publisher","first-page":"1744473","DOI":"10.3389\/fmed.2025.1744473","volume":"12","author":"S Yang","year":"2025","unstructured":"Yang S, et al. The impact of short-term administration of dapagliflozin on contrast-induced acute kidney injury in patients with type 2 diabetes and renal insufficiency undergoing percutaneous coronary intervention. Front Med (Lausanne). 2025;12:1744473.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"3173_CR221","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","volume":"77","author":"M Packer","year":"2021","unstructured":"Packer M. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics. Am J Kidney Dis. 2021;77(2):280\u20136.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"3173_CR222","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrneph.2016.159","volume":"12","author":"K Hahn","year":"2016","unstructured":"Hahn K, et al. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12(12):711\u20132.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"3173_CR223","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/1753-0407.13348","volume":"15","author":"Y Duo","year":"2023","unstructured":"Duo Y, et al. Effect of sodium-glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta-analysis. J Diabetes. 2023;15(1):58\u201370.","journal-title":"J Diabetes"},{"issue":"3","key":"3173_CR224","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","volume":"99","author":"BJ Kraus","year":"2021","unstructured":"Kraus BJ, et al. Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021;99(3):750\u201362.","journal-title":"Kidney Int"},{"issue":"3","key":"3173_CR225","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.kint.2020.11.021","volume":"99","author":"LP Gregg","year":"2021","unstructured":"Gregg LP, Navaneethan SD. Early eGFR decline after SGLT2i initiation: knowns and unknowns. Kidney Int. 2021;99(3):548\u201350.","journal-title":"Kidney Int"},{"key":"3173_CR226","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.2147\/DMSO.S212003","volume":"12","author":"BC Simes","year":"2019","unstructured":"Simes BC, MacGregor GG. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician\u2019s Guide. Diabetes Metab Syndr Obes. 2019;12:2125\u201336.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"3173_CR227","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/phar.1881","volume":"37","author":"KR Burke","year":"2017","unstructured":"Burke KR, Schumacher CA, Harpe SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Pharmacotherapy. 2017;37(2):187\u201394.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"3173_CR228","doi-asserted-by":"publisher","first-page":"722","DOI":"10.4103\/2230-8210.167554","volume":"19","author":"AK Singh","year":"2015","unstructured":"Singh AK. Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight. Indian J Endocrinol Metab. 2015;19(6):722\u201330.","journal-title":"Indian J Endocrinol Metab"},{"issue":"9","key":"3173_CR229","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2337\/dc15-1251","volume":"38","author":"N Erondu","year":"2015","unstructured":"Erondu N, et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care. 2015;38(9):1680\u20136.","journal-title":"Diabetes Care"},{"issue":"1","key":"3173_CR230","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016;101(1):157\u201366.","journal-title":"J Clin Endocrinol Metab"},{"key":"3173_CR231","doi-asserted-by":"publisher","first-page":"204209862198913","DOI":"10.1177\/2042098621989134","volume":"12","author":"R Pelletier","year":"2021","unstructured":"Pelletier R, et al. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther Adv Drug Saf. 2021;12:2042098621989134.","journal-title":"Ther Adv Drug Saf"},{"key":"3173_CR232","doi-asserted-by":"publisher","first-page":"106396","DOI":"10.1016\/j.phrs.2022.106396","volume":"183","author":"ME Lunati","year":"2022","unstructured":"Lunati ME, et al. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol Res. 2022;183:106396.","journal-title":"Pharmacol Res"},{"issue":"12","key":"3173_CR233","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/dom.15249","volume":"25","author":"D Yabe","year":"2023","unstructured":"Yabe D, et al. Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u2265\u200965 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes Obes Metab. 2023;25(12):3538\u201348.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"3173_CR234","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","volume":"106","author":"JH Lim","year":"2022","unstructured":"Lim JH, et al. The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients. Transplantation. 2022;106(9):e404\u201312.","journal-title":"Transplantation"},{"issue":"4","key":"3173_CR235","doi-asserted-by":"publisher","first-page":"108981","DOI":"10.1016\/j.jdiacomp.2025.108981","volume":"39","author":"R Liu","year":"2025","unstructured":"Liu R, et al. Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors\/SGLT-2i. J Diabetes Complications. 2025;39(4):108981.","journal-title":"J Diabetes Complications"},{"issue":"6","key":"3173_CR236","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533\u201343.","journal-title":"N Engl J Med"},{"issue":"6","key":"3173_CR237","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024;149(6):450\u201362.","journal-title":"Circulation"},{"issue":"22","key":"3173_CR238","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, et al. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation. 2024;150(22):1781\u201390.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03173-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03173-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03173-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:29:12Z","timestamp":1781645352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03173-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":238,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3173"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03173-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study is a narrative review, no ethical approval or informed consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}